nodes	percent_of_prediction	percent_of_DWPC	metapath
Mupirocin—Sensitisation—Epirubicin—liver cancer	0.036	0.036	CcSEcCtD
Mupirocin—Sensitisation—Doxorubicin—liver cancer	0.0333	0.0333	CcSEcCtD
Mupirocin—Mouth ulceration—Sorafenib—liver cancer	0.0315	0.0315	CcSEcCtD
Mupirocin—Furunculosis—Epirubicin—liver cancer	0.0303	0.0303	CcSEcCtD
Mupirocin—Eczema—Sorafenib—liver cancer	0.0281	0.0281	CcSEcCtD
Mupirocin—Furunculosis—Doxorubicin—liver cancer	0.028	0.028	CcSEcCtD
Mupirocin—Ulcerative stomatitis—Epirubicin—liver cancer	0.0279	0.0279	CcSEcCtD
Mupirocin—Dermatitis exfoliative—Sorafenib—liver cancer	0.0268	0.0268	CcSEcCtD
Mupirocin—Furuncle—Epirubicin—liver cancer	0.0262	0.0262	CcSEcCtD
Mupirocin—Ulcerative stomatitis—Doxorubicin—liver cancer	0.0258	0.0258	CcSEcCtD
Mupirocin—Furuncle—Doxorubicin—liver cancer	0.0243	0.0243	CcSEcCtD
Mupirocin—Dry skin—Sorafenib—liver cancer	0.0232	0.0232	CcSEcCtD
Mupirocin—Epistaxis—Sorafenib—liver cancer	0.0184	0.0184	CcSEcCtD
Mupirocin—Haemoglobin—Sorafenib—liver cancer	0.0176	0.0176	CcSEcCtD
Mupirocin—Haemorrhage—Sorafenib—liver cancer	0.0175	0.0175	CcSEcCtD
Mupirocin—Stinging—Epirubicin—liver cancer	0.0159	0.0159	CcSEcCtD
Mupirocin—Immune system disorder—Sorafenib—liver cancer	0.0158	0.0158	CcSEcCtD
Mupirocin—Erythema—Sorafenib—liver cancer	0.0152	0.0152	CcSEcCtD
Mupirocin—Dysgeusia—Sorafenib—liver cancer	0.0149	0.0149	CcSEcCtD
Mupirocin—Stinging—Doxorubicin—liver cancer	0.0147	0.0147	CcSEcCtD
Mupirocin—Cellulitis—Epirubicin—liver cancer	0.0141	0.0141	CcSEcCtD
Mupirocin—Angioedema—Sorafenib—liver cancer	0.0139	0.0139	CcSEcCtD
Mupirocin—Cough—Sorafenib—liver cancer	0.0133	0.0133	CcSEcCtD
Mupirocin—Cellulitis—Doxorubicin—liver cancer	0.0131	0.0131	CcSEcCtD
Mupirocin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.0129	0.0129	CcSEcCtD
Mupirocin—Dermatitis contact—Epirubicin—liver cancer	0.0127	0.0127	CcSEcCtD
Mupirocin—Dry mouth—Sorafenib—liver cancer	0.0127	0.0127	CcSEcCtD
Mupirocin—Anaphylactic shock—Sorafenib—liver cancer	0.0124	0.0124	CcSEcCtD
Mupirocin—Skin disorder—Sorafenib—liver cancer	0.0121	0.0121	CcSEcCtD
Mupirocin—Dermatitis contact—Doxorubicin—liver cancer	0.0118	0.0118	CcSEcCtD
Mupirocin—Mouth ulceration—Epirubicin—liver cancer	0.0116	0.0116	CcSEcCtD
Mupirocin—Mouth ulceration—Doxorubicin—liver cancer	0.0108	0.0108	CcSEcCtD
Mupirocin—Pain—Sorafenib—liver cancer	0.0106	0.0106	CcSEcCtD
Mupirocin—Eczema—Epirubicin—liver cancer	0.0104	0.0104	CcSEcCtD
Mupirocin—Gastrointestinal pain—Sorafenib—liver cancer	0.0102	0.0102	CcSEcCtD
Mupirocin—Dermatitis exfoliative—Epirubicin—liver cancer	0.0099	0.0099	CcSEcCtD
Mupirocin—Urticaria—Sorafenib—liver cancer	0.00987	0.00987	CcSEcCtD
Mupirocin—Abdominal pain—Sorafenib—liver cancer	0.00982	0.00982	CcSEcCtD
Mupirocin—Eczema—Doxorubicin—liver cancer	0.00962	0.00962	CcSEcCtD
Mupirocin—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00916	0.00916	CcSEcCtD
Mupirocin—Hypersensitivity—Sorafenib—liver cancer	0.00915	0.00915	CcSEcCtD
Mupirocin—Pruritus—Sorafenib—liver cancer	0.00879	0.00879	CcSEcCtD
Mupirocin—Dry skin—Epirubicin—liver cancer	0.00856	0.00856	CcSEcCtD
Mupirocin—Diarrhoea—Sorafenib—liver cancer	0.0085	0.0085	CcSEcCtD
Mupirocin—Dizziness—Sorafenib—liver cancer	0.00821	0.00821	CcSEcCtD
Mupirocin—Dry skin—Doxorubicin—liver cancer	0.00792	0.00792	CcSEcCtD
Mupirocin—Rash—Sorafenib—liver cancer	0.00783	0.00783	CcSEcCtD
Mupirocin—Dermatitis—Sorafenib—liver cancer	0.00782	0.00782	CcSEcCtD
Mupirocin—Headache—Sorafenib—liver cancer	0.00778	0.00778	CcSEcCtD
Mupirocin—Nausea—Sorafenib—liver cancer	0.00738	0.00738	CcSEcCtD
Mupirocin—Epistaxis—Epirubicin—liver cancer	0.00679	0.00679	CcSEcCtD
Mupirocin—Haemoglobin—Epirubicin—liver cancer	0.00649	0.00649	CcSEcCtD
Mupirocin—Rhinitis—Epirubicin—liver cancer	0.00648	0.00648	CcSEcCtD
Mupirocin—Haemorrhage—Epirubicin—liver cancer	0.00646	0.00646	CcSEcCtD
Mupirocin—Pharyngitis—Epirubicin—liver cancer	0.00641	0.00641	CcSEcCtD
Mupirocin—Epistaxis—Doxorubicin—liver cancer	0.00628	0.00628	CcSEcCtD
Mupirocin—Haemoglobin—Doxorubicin—liver cancer	0.00601	0.00601	CcSEcCtD
Mupirocin—Rhinitis—Doxorubicin—liver cancer	0.00599	0.00599	CcSEcCtD
Mupirocin—Haemorrhage—Doxorubicin—liver cancer	0.00598	0.00598	CcSEcCtD
Mupirocin—Pharyngitis—Doxorubicin—liver cancer	0.00593	0.00593	CcSEcCtD
Mupirocin—Immune system disorder—Epirubicin—liver cancer	0.00584	0.00584	CcSEcCtD
Mupirocin—Erythema—Epirubicin—liver cancer	0.00562	0.00562	CcSEcCtD
Mupirocin—Dysgeusia—Epirubicin—liver cancer	0.00551	0.00551	CcSEcCtD
Mupirocin—Immune system disorder—Doxorubicin—liver cancer	0.0054	0.0054	CcSEcCtD
Mupirocin—Erythema—Doxorubicin—liver cancer	0.0052	0.0052	CcSEcCtD
Mupirocin—Dysgeusia—Doxorubicin—liver cancer	0.0051	0.0051	CcSEcCtD
Mupirocin—Cough—Epirubicin—liver cancer	0.00491	0.00491	CcSEcCtD
Mupirocin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00476	0.00476	CcSEcCtD
Mupirocin—Dry mouth—Epirubicin—liver cancer	0.00468	0.00468	CcSEcCtD
Mupirocin—Anaphylactic shock—Epirubicin—liver cancer	0.00459	0.00459	CcSEcCtD
Mupirocin—Cough—Doxorubicin—liver cancer	0.00454	0.00454	CcSEcCtD
Mupirocin—Skin disorder—Epirubicin—liver cancer	0.00446	0.00446	CcSEcCtD
Mupirocin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.0044	0.0044	CcSEcCtD
Mupirocin—Dry mouth—Doxorubicin—liver cancer	0.00433	0.00433	CcSEcCtD
Mupirocin—Anaphylactic shock—Doxorubicin—liver cancer	0.00425	0.00425	CcSEcCtD
Mupirocin—Skin disorder—Doxorubicin—liver cancer	0.00413	0.00413	CcSEcCtD
Mupirocin—Pain—Epirubicin—liver cancer	0.00393	0.00393	CcSEcCtD
Mupirocin—Gastrointestinal pain—Epirubicin—liver cancer	0.00375	0.00375	CcSEcCtD
Mupirocin—Urticaria—Epirubicin—liver cancer	0.00365	0.00365	CcSEcCtD
Mupirocin—Pain—Doxorubicin—liver cancer	0.00363	0.00363	CcSEcCtD
Mupirocin—Abdominal pain—Epirubicin—liver cancer	0.00363	0.00363	CcSEcCtD
Mupirocin—Gastrointestinal pain—Doxorubicin—liver cancer	0.00347	0.00347	CcSEcCtD
Mupirocin—Hypersensitivity—Epirubicin—liver cancer	0.00338	0.00338	CcSEcCtD
Mupirocin—Urticaria—Doxorubicin—liver cancer	0.00337	0.00337	CcSEcCtD
Mupirocin—Abdominal pain—Doxorubicin—liver cancer	0.00336	0.00336	CcSEcCtD
Mupirocin—Pruritus—Epirubicin—liver cancer	0.00325	0.00325	CcSEcCtD
Mupirocin—Diarrhoea—Epirubicin—liver cancer	0.00314	0.00314	CcSEcCtD
Mupirocin—Hypersensitivity—Doxorubicin—liver cancer	0.00313	0.00313	CcSEcCtD
Mupirocin—Dizziness—Epirubicin—liver cancer	0.00304	0.00304	CcSEcCtD
Mupirocin—Pruritus—Doxorubicin—liver cancer	0.00301	0.00301	CcSEcCtD
Mupirocin—Diarrhoea—Doxorubicin—liver cancer	0.00291	0.00291	CcSEcCtD
Mupirocin—Rash—Epirubicin—liver cancer	0.00289	0.00289	CcSEcCtD
Mupirocin—Dermatitis—Epirubicin—liver cancer	0.00289	0.00289	CcSEcCtD
Mupirocin—Headache—Epirubicin—liver cancer	0.00288	0.00288	CcSEcCtD
Mupirocin—Dizziness—Doxorubicin—liver cancer	0.00281	0.00281	CcSEcCtD
Mupirocin—Nausea—Epirubicin—liver cancer	0.00273	0.00273	CcSEcCtD
Mupirocin—Rash—Doxorubicin—liver cancer	0.00268	0.00268	CcSEcCtD
Mupirocin—Dermatitis—Doxorubicin—liver cancer	0.00268	0.00268	CcSEcCtD
Mupirocin—Headache—Doxorubicin—liver cancer	0.00266	0.00266	CcSEcCtD
Mupirocin—Nausea—Doxorubicin—liver cancer	0.00252	0.00252	CcSEcCtD
